R vs S Ketamine: Arketamine vs Esketamine Explained

R and S ketamine are real, distinct molecules with different pharmacology, and you cannot tell which one you have. Outside a pharmaceutical supply chain, ketamine is racemic: a 50/50 mixture of the two mirror images, (R)-ketamine (arketamine) and (S)-ketamine (esketamine).

S binds the NMDA receptor several times more tightly and is the enantiomer in Spravato. R is the weaker NMDA blocker, and rodent studies suggest it may be the better antidepressant with fewer dissociative and abuse-related effects. That inversion is the genuinely interesting part of the story.

What no reagent kit, fentanyl strip or at-home method can do is separate them, because chirality is invisible to a colour reaction. Anyone selling “R-ketamine” recreationally cannot back the claim, and you cannot check it.

What R and S actually mean

Ketamine has one chiral centre: a carbon with four different groups on it. That produces two non-superimposable mirror images, called enantiomers. Same formula, same molecular weight, same melting point, same solubility. The only difference is three-dimensional shape, and shape is exactly what a protein binding site reads.

Standard ketamine, veterinary and human anaesthetic and recreational alike, is (R,S)-ketamine, an equal mixture. Isolating either one requires a deliberate resolution or asymmetric synthesis step.

S is the potent one

S-ketamine is more potent at the NMDA receptor, which is where most of ketamine’s dissociative and anaesthetic effects run through. Kawczak’s 2024 review in Biomedicines puts numbers on it: esketamine delivers roughly three times the analgesic potency and 1.5 times the anaesthetic potency of arketamine. Against the racemate it gives comparable analgesia with less drowsiness, per Mion’s 2024 work in Anesthesia & Analgesia. Zanos’ 2018 review in Pharmacological Reviews is the standard reference for the receptor pharmacology underneath all of it.

That potency is why S is the enantiomer that got developed and approved, and why it is the drug in Spravato. The differences between Spravato, compounded telehealth ketamine and homemade sprays are covered in the ketamine nasal spray post.

R is the counterintuitive one

If antidepressant action came straight from NMDA blockade, the weaker binder should be the weaker antidepressant. Preclinical work says the reverse. Zhang’s 2022 review in Neuropharmacology states it plainly: a growing body of preclinical studies show arketamine has greater potency and longer-lasting antidepressant-like effects than esketamine in rodents, despite lower NMDA receptor binding affinity, with less psychotomimetic effect, less dissociation and lower abuse liability.

The leading explanation is that ketamine’s antidepressant action is not simply channel block. It runs through downstream events, metabolite activity and synaptic plasticity signalling, that do not track binding affinity. Dissociation, psychotomimetic effects and abuse-related reinforcement do track NMDA potency closely. If those two mechanisms come apart, the weaker NMDA binder can keep the mood effect and shed the side effects. That hypothesis is what arketamine development rests on.

Then the honesty part. Almost all of that advantage is rodent data, and the human evidence is thin and mixed. Leal’s 2021 open-label pilot gave intravenous arketamine at 0.5 mg/kg to 7 people with treatment-resistant depression and reported MADRS scores dropping from 30.7 to 10.4 at one day, with dissociation nearly absent. Seven people, no control, no blinding.

The follow-up was a randomised, double-blind, placebo-controlled crossover pilot in 10 patients, published in the Journal of Affective Disorders in 2023. It found a main effect of time and no significant effect of treatment. Arketamine was safe and well tolerated. It did not beat saline.

A 2025 cross-sectional analysis of registered protocols confirms the shape of the field: arketamine trials remain far smaller and earlier than the esketamine programme. Arketamine is a promising research compound. It is not an established better ketamine, and nobody should sell it as one.

Can you tell what you have? No

Recreational ketamine is racemic, near enough always. Illicit synthesis produces both enantiomers in equal amounts, and getting a single one means a resolution step or asymmetric synthesis, extra equipment, and losing half the yield. There is no market pressure to do that when buyers cannot verify the result anyway. Schmid’s 2020 review of chiral analysis in seized and internet-purchased solid samples found these compound classes are overwhelmingly traded as racemates.

Reagent tests cannot see chirality. Morris and Mandelin react with a functional group and produce a colour, and both enantiomers have identical functional groups, so both give identical colours. The reagent tells you the sample behaves like ketamine and nothing about R versus S. Fentanyl strips are antibody-based and equally blind here. The reagent colour chart covers what those reactions do and do not establish.

Separating enantiomers takes chiral chromatography: a lab instrument with a chiral stationary phase or selector. The same review lists what actually gets used, HPLC, GC, supercritical fluid chromatography, capillary electrophoresis and CEC. Nothing on a spot plate approximates any of it.

So if someone offers you pure R-ketamine, they cannot substantiate it and you cannot check it. Treat it as a sales pitch.

Shards versus powder

“Big shards mean it’s the good stuff” is the most persistent belief about ketamine, and it’s wrong three separate ways.

Texture says nothing about the enantiomer. Crystal habit comes from how the product was recrystallised: which solvent, how fast it cooled, how quickly it evaporated. After that it depends on handling and storage, because ketamine HCl clumps and cakes with humidity, and on whether anyone crushed it in transit. None of those variables involves chirality. Two batches of chemically identical racemic ketamine can look completely different.

Texture is a poor purity signal too. Crystals can be cut, and a pure product can arrive as fine powder purely because of processing. Appearance is not a purity test, and nothing consumer-accessible measures purity or potency.

What texture does change is volume, not potency. A milligram is a milligram regardless of how it looks. But finely ground powder packs far more densely than coarse shards, so the same visually sized line holds meaningfully more drug when the material is finer. Someone eyeballing their usual line after switching from shards to dust can take substantially more than they meant to, with nothing visible to warn them. That is the ordinary explanation for “this batch hit way harder,” far more often than anything about the drug itself.

Which is the argument for weighing instead of eyeballing. A milligram scale deletes the variable, because 40 mg is 40 mg whether it started as shards or powder.

The risks that matter do not care about chirality

Even if you could verify the enantiomer content, it would not change your harm profile. The dose-dependent harms with the best evidence scale with how much and how often, not with stereochemistry.

• Bladder damage. Ketamine-induced uropathy tracks cumulative exposure. See ketamine bladder damage.
• Cognitive effects. Memory and executive function deficits show up in heavy, frequent users. See does ketamine cause brain damage.
• Dependence. Compulsive redosing comes from the short duration and fast tolerance build, not from an isomer ratio. See is ketamine addictive.

R and S really do differ. S is the potent NMDA blocker, R is the surprising preclinical antidepressant candidate, and what you buy is a mixture of both. No consumer test can separate them, and any R-ketamine claim on the recreational market is unverifiable by design. For dose ranges by route, k-hole safety and bladder protection, see the ketamine guide.

Sources

PMID 32540082 | PMID 39457596 | PMID 29945898 | PMID 38295061 | PMID 35977629 | PMID 32078034 | PMID 36871913 | PMID 40440859